Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly today with $90M in funding.
Pathology-Based Deep Learning Tools to Personalize Treatment Decisions:
ArteraAI Prostate Test Development & Validation
Presented by: Tim Showalter, MD, MPH (Monday, February 27, 2023 at 9:45 AM EST)
Jessica Nye from Cancer Therapy Advisor discusses key findings, presented by Daniel Spratt, MD at ASCO GU 2023, demonstrating that Artera’s prognostic MMAI biomarker can more accurately estimate long-term outcomes compared to standard clinicopathologic markers for patients with high-risk prostate cancer.
Urology Times features a video of Daniel Spratt, MD discussing results demonstrating successful validation of Artera’s MMAI prognostic biomarker in high-risk prostate cancer.
Mark Leiser from HemOnc Today discusses results from Artera’s prognostic MMAI model that were presented by Daniel Spratt, MD at ASCO GU 2023. The article includes a perspective from Eric Horwitz, MD, FABS, FASTRO.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer: Results From Six NRG/RTOG Phase III
Randomized Trials
Presented by: Daniel Spratt, MD (Thursday, February 16, 2023 at 8:42 AM PST)
Andre Esteva, Co-founder and CEO of Artera, discusses how AI can support the ACS’ IMPACT initiative and other possibilities in the healthcare industry.
